Published in Am J Gastroenterol on August 01, 2004
Safety Trial of Herbal Melanin in Gastritis Patients (RASATHEME) | NCT03428568
Relationship between history, laryngoscopy and esophagogastroduodenoscopy for diagnosis of laryngopharyngeal reflux in patients with typical GERD. Eur Arch Otorhinolaryngol (2011) 1.50
Extraoesophageal manifestations of gastro-oesophageal reflux. Gut (2005) 1.40
Barrett's esophagus and the increasing role of endoluminal therapy. Therap Adv Gastroenterol (2008) 1.11
Globus pharyngeus: a review of its etiology, diagnosis and treatment. World J Gastroenterol (2012) 1.10
The gastrointestinal aspects of halitosis. Can J Gastroenterol (2010) 0.92
Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg (2011) 0.88
Association of laryngopharyngeal manifestations and gastroesophageal reflux. Eur Arch Otorhinolaryngol (2008) 0.86
The oesophagus and cough: laryngo-pharyngeal reflux, microaspiration and vagal reflexes. Cough (2013) 0.85
Comparative outcomes of antireflux treatment for laryngopharyngeal reflux symptoms and upper abdominal symptoms in patients with endoscopic esophagitis. Eur Arch Otorhinolaryngol (2010) 0.79
Should upper gastrointestinal endoscopy be part of the evaluation for supraesophageal symptoms of GERD? Am J Gastroenterol (2004) 0.78
The role of (duodeno)gastroesophagopharyngeal reflux in unexplained excessive throat phlegm. Dig Dis Sci (2005) 0.77
Paroxysmal laryngospasm: a typical but underrecognized supraesophageal manifestation of gastroesophageal reflux? Dig Dis Sci (2005) 0.77
Determinants of long-term outcome of patients with reflux-related ear, nose, and throat symptoms. Dig Dis Sci (2006) 0.77
Does endoscopic appearance of esophagus always suffice the diagnosis of esophagitis in patients presenting with otolaryngologic symptoms? Am J Gastroenterol (2005) 0.75
Halitosis and helicobacter pylori infection: A meta-analysis. Medicine (Baltimore) (2016) 0.75
GERD: 'silent refluxers'. Med J Armed Forces India (2011) 0.75
ENT Symptoms of GERD. Gastroenterol Hepatol (N Y) (2006) 0.75
Can gastro-oesophageal reflux be predicted while advancing the endoscope through the laryngeal area? Gut (2005) 0.75
Manifestations of gastro-pharyngo-laryngeal reflux disease. Acta Otorhinolaryngol Ital (2006) 0.75
Regional Variability of Repeat Esophagogastroduodenoscopy Use in the National Veteran Population. Dig Dis Sci (2017) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med (2011) 6.76
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology (2007) 4.58
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36
Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology (2012) 3.35
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol (2004) 2.99
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 2.94
The complexity of feeding problems in 700 infants and young children presenting to a tertiary care institution. J Pediatr Gastroenterol Nutr (2003) 2.86
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2008) 2.67
A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut (2011) 2.66
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut (2011) 2.58
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology (2003) 2.37
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26
Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut (2013) 2.26
The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol (2013) 2.21
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet (2007) 2.14
Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol (2009) 2.10
Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med (2009) 2.10
Pro: Impedance testing is useful in the management of GERD. Am J Gastroenterol (2009) 2.09
Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med (2014) 2.05
Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol (2003) 2.04
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology (2013) 2.04
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut (2013) 2.03
Characteristics and clinical relevance of proximal esophageal pH monitoring. Am J Gastroenterol (2004) 2.01
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology (2009) 2.00
C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.92
Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res (2004) 1.88
Reproducibility and agreement of pharyngeal automated impedance manometry with videofluoroscopy. Clin Gastroenterol Hepatol (2011) 1.84
Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology (2013) 1.83
A novel method for the nonradiological assessment of ineffective swallowing. Am J Gastroenterol (2011) 1.81
Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis (2006) 1.79
Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis (2010) 1.74
Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet (2010) 1.72
Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying. Proc Natl Acad Sci U S A (2011) 1.69
Long-term outcome of transcatheter embolotherapy for acute lower gastrointestinal hemorrhage. Am J Gastroenterol (2009) 1.69
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut (2007) 1.64
Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol (2013) 1.61
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Nerve activity recordings in routine human intestinal biopsies. Gut (2012) 1.59
Regional brain activation during proximal stomach distention in humans: A positron emission tomography study. Gastroenterology (2005) 1.58
Gastric fullness, physical activity, and proximal extent of gastroesophageal reflux. Am J Gastroenterol (2005) 1.56
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol (2003) 1.55
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology (2002) 1.55
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol (2011) 1.53
Crohn's disease and month of birth. Inflamm Bowel Dis (2005) 1.53
Management of acute severe ulcerative colitis. Gut (2010) 1.53
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology (2003) 1.52
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol (2013) 1.50
Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol (2004) 1.50
Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology (2007) 1.48
Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology (2005) 1.46
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol (2005) 1.44
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol (2007) 1.39
Common trunk of superior and inferior mesenteric artery at the level of the fifth lumbar vertebra. J Vasc Interv Radiol (2010) 1.39
Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol (2009) 1.37
Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis (2008) 1.36
A method to objectively assess swallow function in adults with suspected aspiration. Gastroenterology (2011) 1.35